Statins and asthma: Where we stand, and the next critical steps in research

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.

Original languageEnglish (US)
Pages (from-to)1051-1054
Number of pages4
JournalCurrent Medical Research and Opinion
Volume30
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Asthma
Research
Costs and Cost Analysis
Clinical Trials
Investigational Therapies
Centers for Disease Control and Prevention (U.S.)
Observational Studies
Hospital Emergency Service
Hospitalization
Public Health

Keywords

  • Asthma
  • Exacerbation
  • Inhaled corticosteroids
  • Statin
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Statins and asthma : Where we stand, and the next critical steps in research. / Zeki, Amir.

In: Current Medical Research and Opinion, Vol. 30, No. 6, 2014, p. 1051-1054.

Research output: Contribution to journalArticle

@article{0401aeb1161c4bcda05cf0280dbc172a,
title = "Statins and asthma: Where we stand, and the next critical steps in research",
abstract = "Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.",
keywords = "Asthma, Exacerbation, Inhaled corticosteroids, Statin, Statins",
author = "Amir Zeki",
year = "2014",
doi = "10.1185/03007995.2014.881794",
language = "English (US)",
volume = "30",
pages = "1051--1054",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Statins and asthma

T2 - Where we stand, and the next critical steps in research

AU - Zeki, Amir

PY - 2014

Y1 - 2014

N2 - Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.

AB - Asthma remains a formidable public health problem with ever increasing annual costs and prevalence. There are 300 million people with asthma worldwide. Per the Centers for Disease Control and Prevention, there are over 25 million Americans with asthma (both children and adults), i.e. one in 12 people have asthma, and this is increasing annually. Asthma results in approximately half a million hospitalizations and two million emergency department (ED) visits per year. In 2007 alone, 185 children and 3262 adults died from asthma, i.e. nine to ten patients die a day from asthma. This resulted in an annual cost of $56 billion in medical costs, lost work/school days, and early deaths. Therefore, we need novel and innovative therapies for asthma. In this Editorial, I review results from a study by Tse et al. evaluating the therapeutic potential of statins, within the context of our current state of knowledge. I review observational studies and clinical trials, highlight some potential pitfalls in clinical trial design, and discuss important questions for future research.

KW - Asthma

KW - Exacerbation

KW - Inhaled corticosteroids

KW - Statin

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84900823006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900823006&partnerID=8YFLogxK

U2 - 10.1185/03007995.2014.881794

DO - 10.1185/03007995.2014.881794

M3 - Article

C2 - 24450485

AN - SCOPUS:84900823006

VL - 30

SP - 1051

EP - 1054

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 6

ER -